SEC Form 4 · accession 0000899243-18-017963

Tectonic Therapeutic, Inc. · TECX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 25, 2018

Accepted (ET)

Jun 25, 2018 · 6:15 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001681087

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jun 25, 2018	C	806,711	—	A	806,711	I	See Footnote
Common Stock^F3,F2	Jun 25, 2018	C	3,044,579	—	A	3,851,290	I	See Footnote
Common Stock^F4,F2	Jun 25, 2018	C	905,188	—	A	4,756,478	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series Seed Preferred Stock^F2,F3,F5	—	Jun 25, 2018	C	3,333,333	D	—	—	Common Stock	806,711	I
Series A Preferred Stock^F2,F3,F5	—	Jun 25, 2018	C	12,580,199	D	—	—	Common Stock	3,044,579	I
Series B Preferred Stock^F2,F3,F5	—	Jun 25, 2018	C	3,740,239	D	—	—	Common Stock	905,188	I

F1Represents the total number of shares of Common Stock received by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"), upon the conversion of the Issuer's Series Seed Preferred Stock in connection with the closing of the Issuer's initial public offering.
F2The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
F3Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
F4Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
F5All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.